ATXI · Avenue Therapeutics, Inc. · Metrics
$0.38
-0.05 (-10.71%)
At close · Mar 19
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, as described below, substantial doubt about the Company’s ability to continue as a going concern exists. These factors individually and collectively cause substantial doubt about the Company’s ability to continue as a going concern to exist within one year from the date of this report.”View the 10-Q filed Nov 6, 2026
Market Cap
$848,783
Shares
3.29M
Volume · Mar 19
173.84K
Avg daily vol (3M)
426.7K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
ATXI metrics
38 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$0.38
Market cap
$848,783
Price action
23 metricsPrice change (1W)
-60.3%
Price change (30D)
—
Price change (3M)
-79.6%
Price change (6M)
-86.1%
Price change (YTD)
-81.3%
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
$12.00
52-week low
$0.38
Change from 52-week high
-96.9%
Change from 52-week low
+0.0%
Annualized volatility
98.6%
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
17.1
Price vs SMA 50
-72.1%
Price vs SMA 200
-83.5%
Avg volume (3M)
426,696
Relative volume
0.4
Average dollar volume
$738,078
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
3.29M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-328.1%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
-219.6%
Trailing 12 months
Net margin
-207.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$2.88M
Net income (TTM)
−$2.79M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+3.5%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-182.0%
Debt / equity
—
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
7.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$1.52M
Latest balance sheet
Cash & equivalents
$1.52M
Total assets
$1.53M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$2.19M
Capital expenditures (TTM)
—
R&D (TTM)
$916,000
SG&A (TTM)
—
Stock compensation (TTM)
$311,000
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—
Ownership (registered funds)
1 metricsIndex-fund ownership
0.0%
Short interest
3 metricsShort interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged